CG Oncology
PublicCG Oncology is now publicly traded
The data on this page reflects CG Oncology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jan 24, 2024
Last Round
Follow-on Offering
Dec 16, 2024
Total Funding Raised
$1.1B
Company Overview
CG Oncology (NAS: CGON) is a biopharmaceutical company dedicated to developing and commercializing innovative bladder-sparing therapies for patients with bladder cancer.
Sector
Biotech
AI Layer
Non-AI
Keywords
CG Oncology Comparables
Compare CG Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Abalos Therapeutics | 52% | |
| Emtora Biosciences | 51% | |
| Omios Biologics | 51% |
For institutional investors. Book with your work email.
CG Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Dec 16, 2024 | ||||
| IPO | Jan 24, 2024 | ||||
| Crossover Round | Aug 2, 2023 | ||||
| Series F | Jul 1, 2023 | ||||
| Series E | Nov 15, 2022 | ||||
Series D | Dec 10, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CG Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Sirona Capital | Series E |
| Longitude Capital | Series F, Crossover Round, Series E |
| Janus Henderson Group | Series F, Crossover Round |
| RA Capital Management | Series F, Crossover Round, Series E |
| TCG Crossover | Series F, Crossover Round |
| Morgan Stanley & Co., LLC | Follow-on Offering |
| Camford Capital | Series D |
For institutional investors. Book with your work email.
CG Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.